MedTrace Logo

Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer

NCT05872204 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-05-05

No results posted yet for this study

Summary

The purpose of this study is to assess the efficacy and safety of abemaciclib and letrozole for treatment of estrogen receptor-positive rare ovarian cancer.

Conditions

  • Low Grade Serous Ovarian Carcinoma
  • Adult Type Granulosa Cell Tumor

Interventions

DRUG

Abemaciclib

150 mg tablet twice daily

DRUG

Letrozole

2.5 mg tablet once daily

Sponsors & Collaborators

  • Kom Op Tegen Kanker

    collaborator OTHER

  • Eli Lilly and Company

    collaborator INDUSTRY

  • European Network of Gynaecological Oncological Trial Groups (ENGOT)

    collaborator OTHER

  • Universitaire Ziekenhuizen KU Leuven

    lead OTHER

Principal Investigators

  • Els Van Nieuwenhuysen, MD PhD · UZ Leuven

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-30
Primary Completion
2028-01-31
Completion
2028-01-31
FDA Drug
Yes

Countries

  • Belgium
  • France
  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05872204 on ClinicalTrials.gov